Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Moderna Inc
MRNA
Healthcare
Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular...
, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:MRNA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
(80)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 09, 2024 12:15pm
Moderna Inc. (NASDAQ: MRNA) Leading the Way in Tuesday Tradi
NEWS: $MRNA Moderna Inc. (NASDAQ: MRNA) Leading the Way in Tuesday Trading Based on Percentage GainModerna, Inc. (NASDAQ: MRNA) is one of today's top gainers. The company's shares have moved 8
...more
(80)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 26, 2024 7:30pm
Reduce Recommendation Issued On MRNA By HSBC
Just In: $MRNA Reduce Recommendation Issued On MRNA By HSBC2024-02-26 09:15:03 ET HSBC analyst issues REDUCE recommendation for MRNA on February 26, 2024 08:11AM ET. The previous analyst
...more
Q Precious & Battery Metals to Drill Initial 1000 metres at La Corne and McKenzie East Gold Projects, Quebec
posted Apr 18, 2024 9:00am by
Q Precious & Battery Metals Corp
-
|
The Company is planning for an initial 1,000 metres of diamond drilling scheduled for mid- June 2024, with VMS targets on the La Corne South project at proposed depths ranging from 50 to 300 metres below surface as modelled by the EM survey and noted in historic drilling. TMC Geophysique completed deep-penetrating Pulse-EM -Time Domain Electromagnetic (TDEM) surveying on the claims that targeted ...read more
(80)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 02, 2024 1:00pm
Moderna Stock Is Moving Higher: What's Going On? | Benzinga
JUST IN: $MRNA Moderna Stock Is Moving Higher: What's Going On? | BenzingaModerna@Inc (NASDAQ: MRNA) shares are trading higher Tuesday following positive analyst coverage from Oppenheimer.What
...more
(0)
•••
rizashakur29
X
View Profile
View Bullboard History
Post by
rizashakur29
on Nov 18, 2022 12:40pm
Hurry up....
hThis site just sent me a 68% winner. ttp://stockscreener.tech
(433)
•••
AwareInvestor
X
View Profile
View Bullboard History
Post by
AwareInvestor
on Aug 04, 2022 8:30am
Moderna Shares Soar As Company Announces $3 Billion Stock Bu
Moderna Inc shares on Wednesday soared as high as 17% after it announced that it would be buying back up to US$3 billion of its stock when it reported its second-quarter earnings. But not everyone’s
...more
(18325)
•••
Joe455
X
View Profile
View Bullboard History
Comment by
Joe455
on May 29, 2022 10:39am
RE:News BioVaxys Confirms First Clinical Site and Principal In
Sounds very promising
(2805)
•••
frankman
X
View Profile
View Bullboard History
Post by
frankman
on May 18, 2022 9:20am
News BioVaxys Confirms First Clinical Site and Principal In
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement VANCOUVER, BC, May 18, 2022
...more
(2805)
•••
frankman
X
View Profile
View Bullboard History
Post by
frankman
on Apr 27, 2022 10:14am
BioVaxys CEO shares op ed - top Canadian political website
https://www.ipolitics.ca/sponsored/research-on-a-universal-sarbecovirus-vaccine-well-underway
(2805)
•••
frankman
X
View Profile
View Bullboard History
Post by
frankman
on Apr 25, 2022 10:22am
BioVaxys Enters Critical Tumor Cell Supply Agreement
For BVX-0918 Bioproduction VANCOUVER, BC, April 25, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or "Company"
...more
(4)
•••
johnfever21
X
View Profile
View Bullboard History
Post by
johnfever21
on Mar 30, 2022 8:06am
BioVaxys Expands Cancer Vaccine Platform
BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC, March 30, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF)
...more
(433)
•••
AwareInvestor
X
View Profile
View Bullboard History
Post by
AwareInvestor
on Mar 24, 2022 8:54am
Moderna To Construct Manufacturing Facility In Australia Und
Moderna Inc is officially going to the land down under. The company late last night announced that it has finalized a strategic partnership with the Australian federal government that will see a
...more
(2)
•••
randtr
X
View Profile
View Bullboard History
Post by
randtr
on Mar 17, 2022 9:11am
BioVaxys Announces Bioproduction of BVX-1021 for its
BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University VANCOUVER, BC, March 17, 2022 /PRNewswire/ -- BioVaxys
...more
(42)
•••
Okanagan
X
View Profile
View Bullboard History
Comment by
Okanagan
on Mar 16, 2022 3:08pm
RE:how is it when you get your shots plus buster shot you get
The first mistake you made was he believed a politician. You got to realize Pfizer and moderna are two of the most unethical stocks you can buy it's blood Money bad things will happen to you if
...more
(42)
•••
Okanagan
X
View Profile
View Bullboard History
Comment by
Okanagan
on Mar 16, 2022 3:05pm
RE:RE:how is it when you get your shots plus buster shot you get
When is this Insanity going to stop. This is mass in inilation of the populace. They will all pay someday
(31)
•••
Nick1969
X
View Profile
View Bullboard History
Comment by
Nick1969
on Feb 22, 2022 8:08pm
RE:how is it when you get your shots plus buster shot you get
We all are going to die one day..Some sooner than others..
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Positive PEA for Uranium-Vanadium Deposit After-tax NPV 8%: $227.7 million with IRR: 38.9%
Fokus Mining Welcomes Luc Gervais To Its Board Of Directors
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Q Precious & Battery Metals Contracts First Class Drilling for Quebec Projects
Why the Tonopah Gold Project is One to Watch
Targeting Nevada and Ontario for the Critical Minerals Supply Chain
Asset Sale Allows Biotech Company to Refocus on the High Value Dermatological Market